Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with low-intensity metronomic decitabine and venetoclax.
A new drug combination shows promise for patients with hard-to-treat blood cancers where standard therapies have struggled.
This study reports on a novel low-intensity decitabine plus venetoclax combination for the extremely poor-prognosis group of TP53-mutated MDS and AML patients. The approach demonstrates clinical activity in a population where existing therapies have shown limited benefit.
What the study was
- Study design
- Multi-center clinical trial (prospective)
- Population
- Adults with TP53-mutated MDS and AML
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Haematologica
Why it surfaced
TP53-mutated MDS/AML has critical unmet need with poor outcomes under current standard of care. Novel metronomic decitabine+venetoclax approach directly addresses highest-need hematologic malignancy subgroup. Published in top-tier hematology journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.